Navigation Links
Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
Date:7/9/2009

SHANGHAI, July 9 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd., (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, today announces that it has expanded its integrated drug discovery research collaboration with Agios, the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of cancer metabolism. ChemPartner will provide integrated services in the areas of protein science, HTS, in vitro enzyme assay, cell biology, in vivo pharmacology, etc., for Agios' innovative R&D program to discover novel clinical candidates for oncology indications.

Michael Hui, founder and CEO of ChemPartner, said, "ChemPartner is pleased to build upon this existing collaboration and work closely with the experienced scientists at Agios to develop new clinical compounds for oncology indications. The partnership demonstrates the strength and breadth of our integrated drug discovery and development capabilities and this is a wonderful opportunity to share expertise and complement strengths."

"Due to the rapid success and progression of our pipeline and platform, Agios has experienced a need for significant resource assistance. ChemPartners has been able to help us address these needs quickly with high quality and quick responsiveness," said Michael Su, Vice President of Drug Discovery, Agios Pharmaceuticals. "ChemPartners' flexibility, scientific expertise, problem-solving skills as well as its comprehensive and integrated service platform have made them an invaluable partner in our continuing leadership strategy of the exciting, breakthrough field of cancer metabolism."

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 80 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1,000 scientists including over 80 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at http://www.shangpharma.com .


'/>"/>
SOURCE Shanghai ChemPartner Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007
2. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
3. Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference
4. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
5. Shanghai CRO Service Alliance Adds Clinical Development Capabilities
6. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
7. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
8. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
9. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- ATCC, the premier global biological materials resource and ... life science researchers that are working to address the ... CDC website . --> CDC website ... single-stranded RNA virus of the Flaviviridae family, genus Flavivirus, ... Viruses. Zika virus is transmitted to humans primarily through ...
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/5/2016)... Feb. 5, 2016 Australian-US drug discovery and development ... the appointment of a new Chairman, Mr John O,Connor ... effective immediately. James Garner , has also ... and former Acting CEO, Mr Iain Ross , will ... --> James Garner , has also been formally ...
(Date:2/4/2016)... , February 4, 2016 - New FDA action ... - New FDA action date of July 22, ... July 22, 2016   - ... in the past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):